The bedside arrival of blockbuster medicines like ibrutinib and osimertinib changed the narrative on oncogene-driven cancers. How? Cysteine. Reporting in 2024, Takahashi et al. comprehensively map the covalently targetable cysteines across 416 cancer models, defining biological and structural principles of target tractability. Welcome to DrugMap.